Table 1 Demographic and clinical characteristics of case patients infected with IRAB, compared with non-infected control patients
Characteristica | Cases (n = 11) | Controls (n = 14) | P value |
|---|---|---|---|
Age (years) | 65.09 ± 12.65 | 63.86 ± 14.33 | 0.824 |
Gender, male (%) | 5 (45.46) | 5 (35.71) | 0.622 |
Prior hospital stay (<1 year) | 3 (27.27) | 2 (14.29) | 0.420 |
Length of stay in ICU (days) | 6 (3–25) | 11 (2.75–25.75) | 0.784 |
APACHE II score upon ICU admission | 21.82 ± 7.13 | 21.50 ± 8.04 | 0.919 |
SOFA score upon ICU admission | 6.55 ± 3.14 | 7.00 ± 6.49 | 0.762 |
Primary ICU admission diagnosis | |||
Chronic pulmonary disease | 8 (72.72) | 4 (28.57) | 0.028 |
Pneumonia | 8 (72.72) | 8 (57.14) | 0.42 |
Diabetes mellitus | 1 (9.09) | 2 (14.28) | 0.692 |
Hypertension | 2 (18.18) | 5 (35.71) | 0.332 |
Malignancy | 2 (18.18) | 3 (21.42) | 0.84 |
Surgery procedure (<30 days) | 1 (9.09) | 5 (35.71) | 0.122 |
Antibiotic classesb | |||
Carbapenem | 7 (63.63) | 6 (42.86) | 0.302 |
Penicillins | 3 (27.27) | 6 (42.56) | 0.420 |
Piperacillin/tazobactam | 5 (45.45) | 6 (42.86) | 0.897 |
Cefepime | 7 (63.63) | 6 (42.86) | 0.302 |
Fluoroquinolones | 3 (27.28) | 3 (21.42) | 0.734 |
Glycopeptide | 6 (54.54) | 8 (57.14) | 0.716 |
Antifungal | 4 (36.36) | 4 (28.57) | 0.678 |
ICU procedures | |||
Ventilator | 11 (100) | 14 (100) | -- |
Blood transfusion | 5 (45.45) | 7 (50) | 0.821 |
Hemodialysis | 0 (0) | 4 (28.57) | 0.053 |
Nasogastric tube | 11 (100) | 12 (85.71) | 0.191 |
Venous central catheter | 10 (81.82) | 13 (92.86) | 0.859 |
Peripheral venous catheter | 11 (100) | 13 (92.86) | 0.366 |
Arterial catheter | 4 (36.36) | 6 (42.86) | 0.742 |
Urinary catheter | 11 (100) | 14 (100) | -- |
Outcome | |||
28-day mortality | 3 (27.27) | 2 (14.29) | 0.420 |
Hospital mortality | 6 (54.56) | 3 (21.42) | 0.032 |